GDUFA III Rate Increase and Regulatory Funding

The U.S. Food and Drug Administration (FDA) is increasing generic drug user fees for fiscal year 2026 (FY 2026) under the Generic Drug User Fee Amendments III (GDUFA III), increasing the financial burden on the industry. Under the amendment, the Abbreviated New Drug Application (ANDA) fee, a critical gateway for generic drug launches, has been adjusted to USD 358,247, a significant increase of approximately 11.3% from the previous fiscal year's USD 321,920. In addition, the Drug Master File (DMF) review fee has also been increased to USD 102,584, and overall approval costs from raw materials to finished products have been uniformly increased. This sharp increase in fee rates reflects the FDA's strong commitment to strengthening the administrative capacity of the review department and securing resources to align with increasingly sophisticated standards for biologics analysis.

Administrative Digitization and Challenges for Small and Medium-Sized Developers

With the increase in regulatory costs, the full digitization of the payment administration system has also been implemented, making it urgent for the industry to adapt practically. The FDA will completely discontinue the previous paper-based and mail-based fee payment methods from October 1, 2025, and will mandate a 100% electronic payment transition. This is intended to resolve inconsistencies between approval documents and cost settlements to increase the predictability of reviews, but it may pose an administrative hurdle for global small and medium-sized pharmaceutical companies, requiring immediate system upgrades. Ultimately, the IT infrastructure costs hidden behind the rationale of streamlining reviews are making the market qualification assessment of companies with weak technological capabilities even more stringent.

Pressure on Generic Market Margins and the Defense of Large Companies

The generic sector, which supplies approximately 90% of prescription drugs in the United States, has an extremely low profit margin relative to sales and is highly sensitive to rising fixed costs. Companies such as Teva Pharmaceutical Industries (TEVA), Viatris (VTRS), and Sandoz Group (SDZNY) can easily absorb the annual program fees, which amount to millions of dollars. However, small and medium-sized generic developers with a limited number of products may face a financial vicious cycle in which they have to raise the selling price of a single product or reduce the bioequivalence testing phase in order to recover fixed regulatory costs.

Value Chain Restructuring and Roadmap for Next-Generation Agreements

With the sunset of GDUFA III in September 2027, the industry and regulatory agencies have already begun discussions to establish the framework for the next-generation agreement, GDUFA IV (FY 2028 ~ FY 2032). Investors should pay attention to the leading companies with cost control capabilities and digital compliance capabilities, which will expand their market share, rather than small and medium-sized pharmaceutical companies that will lose competitiveness and be eliminated in the rising fee environment. In the medium to long term, the generic industry will shift rapidly from a simple generic drug market to a market with high technological barriers to entry, such as complex generics and biosimilars, and companies that have proactively invested in this area will hold the key to long-term survival.